Article
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
Journal of clinical microbiology - 1 Jun 2006
Osiowy Carla, Villeneuve Jean-Pierre, Heathcote E Jenny, Giles Elizabeth, Borlang Jamie
Abstract excerpt
The nucleotide analog adefovir dipivoxil (ADV) is an effective antiviral treatment for chronic hepatitis B virus (HBV) infection, with resistance to ADV estimated to occur less frequently than resistance to lamivudine treatment. The detection of ADV resistance mutations is necessary during therapy to monitor and anticipate possible treatment failure. The INNO-LiPA HBV DR v2 (LiPA; Innogenetics, Ghent, Belgium) is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
